Does misery love company?: evidence from pharmaceutical markets before and after the Orphan Drug Act
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Cambridge, Mass.
National Bureau of Economic Research
2003
|
| Schriftenreihe: | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series
9750 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | 21, [8] S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV023590396 | ||
| 003 | DE-604 | ||
| 005 | 20090717 | ||
| 007 | t | ||
| 008 | 021128s2003 xxud||| |||| 00||| eng d | ||
| 035 | |a (OCoLC)52500598 | ||
| 035 | |a (DE-599)BVBBV023590396 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 044 | |a xxu |c XD-US | ||
| 049 | |a DE-521 |a DE-19 | ||
| 050 | 0 | |a HB1 | |
| 082 | 0 | |a 330.072 | |
| 100 | 1 | |a Lichtenberg, Frank R. |d 1951- |e Verfasser |0 (DE-588)12863717X |4 aut | |
| 245 | 1 | 0 | |a Does misery love company? |b evidence from pharmaceutical markets before and after the Orphan Drug Act |c Frank R. Lichtenberg ; Joel Waldfogel |
| 264 | 1 | |a Cambridge, Mass. |b National Bureau of Economic Research |c 2003 | |
| 300 | |a 21, [8] S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 9750 | |
| 610 | 2 | 4 | |a United States. |t Orphan Drug Act |
| 650 | 4 | |a Drug Industry |x economics |z United States | |
| 650 | 4 | |a Drugs |x Research |z United States | |
| 650 | 4 | |a Drugs |z United States | |
| 650 | 4 | |a Federal aid to research |z United States | |
| 650 | 4 | |a Marketing |z United States | |
| 650 | 4 | |a New products | |
| 650 | 4 | |a Orphan Drug Production |z United States | |
| 650 | 4 | |a Public health |z United States | |
| 650 | 4 | |a Research |z United States | |
| 650 | 4 | |a Tax credits |z United States | |
| 651 | 4 | |a USA | |
| 700 | 1 | |a Waldfogel, Joel |d 1962- |e Verfasser |0 (DE-588)124748112 |4 aut | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |
| 830 | 0 | |a National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |v 9750 |w (DE-604)BV002801238 |9 9750 | |
| 856 | 4 | 1 | |u http://papers.nber.org/papers/w9750.pdf |z kostenfrei |3 Volltext |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016905726 | ||
Datensatz im Suchindex
| _version_ | 1804138246407454720 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Lichtenberg, Frank R. 1951- Waldfogel, Joel 1962- |
| author_GND | (DE-588)12863717X (DE-588)124748112 |
| author_facet | Lichtenberg, Frank R. 1951- Waldfogel, Joel 1962- |
| author_role | aut aut |
| author_sort | Lichtenberg, Frank R. 1951- |
| author_variant | f r l fr frl j w jw |
| building | Verbundindex |
| bvnumber | BV023590396 |
| callnumber-first | H - Social Science |
| callnumber-label | HB1 |
| callnumber-raw | HB1 |
| callnumber-search | HB1 |
| callnumber-sort | HB 11 |
| callnumber-subject | HB - Economic Theory and Demography |
| ctrlnum | (OCoLC)52500598 (DE-599)BVBBV023590396 |
| dewey-full | 330.072 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 330 - Economics |
| dewey-raw | 330.072 |
| dewey-search | 330.072 |
| dewey-sort | 3330.072 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01839nam a2200481zcb4500</leader><controlfield tag="001">BV023590396</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20090717 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">021128s2003 xxud||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)52500598</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023590396</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">xxu</subfield><subfield code="c">XD-US</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-521</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">HB1</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">330.072</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lichtenberg, Frank R.</subfield><subfield code="d">1951-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)12863717X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Does misery love company?</subfield><subfield code="b">evidence from pharmaceutical markets before and after the Orphan Drug Act</subfield><subfield code="c">Frank R. Lichtenberg ; Joel Waldfogel</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, Mass.</subfield><subfield code="b">National Bureau of Economic Research</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">21, [8] S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">9750</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">United States.</subfield><subfield code="t">Orphan Drug Act</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Industry</subfield><subfield code="x">economics</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Research</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Federal aid to research</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Marketing</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">New products</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Orphan Drug Production</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Public health</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Research</subfield><subfield code="z">United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tax credits</subfield><subfield code="z">United States</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waldfogel, Joel</subfield><subfield code="d">1962-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)124748112</subfield><subfield code="4">aut</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series</subfield><subfield code="v">9750</subfield><subfield code="w">(DE-604)BV002801238</subfield><subfield code="9">9750</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://papers.nber.org/papers/w9750.pdf</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016905726</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV023590396 |
| illustrated | Illustrated |
| index_date | 2024-07-02T22:41:26Z |
| indexdate | 2024-07-09T21:25:08Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016905726 |
| oclc_num | 52500598 |
| open_access_boolean | 1 |
| owner | DE-521 DE-19 DE-BY-UBM |
| owner_facet | DE-521 DE-19 DE-BY-UBM |
| physical | 21, [8] S. graph. Darst. |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | National Bureau of Economic Research |
| record_format | marc |
| series | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| series2 | National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series |
| spelling | Lichtenberg, Frank R. 1951- Verfasser (DE-588)12863717X aut Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act Frank R. Lichtenberg ; Joel Waldfogel Cambridge, Mass. National Bureau of Economic Research 2003 21, [8] S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 9750 United States. Orphan Drug Act Drug Industry economics United States Drugs Research United States Drugs United States Federal aid to research United States Marketing United States New products Orphan Drug Production United States Public health United States Research United States Tax credits United States USA Waldfogel, Joel 1962- Verfasser (DE-588)124748112 aut Erscheint auch als Online-Ausgabe National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series 9750 (DE-604)BV002801238 9750 http://papers.nber.org/papers/w9750.pdf kostenfrei Volltext |
| spellingShingle | Lichtenberg, Frank R. 1951- Waldfogel, Joel 1962- Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act National Bureau of Economic Research <Cambridge, Mass.>: NBER working paper series United States. Orphan Drug Act Drug Industry economics United States Drugs Research United States Drugs United States Federal aid to research United States Marketing United States New products Orphan Drug Production United States Public health United States Research United States Tax credits United States |
| title | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act |
| title_auth | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act |
| title_exact_search | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act |
| title_exact_search_txtP | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act |
| title_full | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act Frank R. Lichtenberg ; Joel Waldfogel |
| title_fullStr | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act Frank R. Lichtenberg ; Joel Waldfogel |
| title_full_unstemmed | Does misery love company? evidence from pharmaceutical markets before and after the Orphan Drug Act Frank R. Lichtenberg ; Joel Waldfogel |
| title_short | Does misery love company? |
| title_sort | does misery love company evidence from pharmaceutical markets before and after the orphan drug act |
| title_sub | evidence from pharmaceutical markets before and after the Orphan Drug Act |
| topic | United States. Orphan Drug Act Drug Industry economics United States Drugs Research United States Drugs United States Federal aid to research United States Marketing United States New products Orphan Drug Production United States Public health United States Research United States Tax credits United States |
| topic_facet | United States. Orphan Drug Act Drug Industry economics United States Drugs Research United States Drugs United States Federal aid to research United States Marketing United States New products Orphan Drug Production United States Public health United States Research United States Tax credits United States USA |
| url | http://papers.nber.org/papers/w9750.pdf |
| volume_link | (DE-604)BV002801238 |
| work_keys_str_mv | AT lichtenbergfrankr doesmiserylovecompanyevidencefrompharmaceuticalmarketsbeforeandaftertheorphandrugact AT waldfogeljoel doesmiserylovecompanyevidencefrompharmaceuticalmarketsbeforeandaftertheorphandrugact |